Drug Profile
MK 8368
Alternative Names: MK-8368Latest Information Update: 08 Aug 2011
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Neuropsychotherapeutics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psychiatric disorders
Most Recent Events
- 08 Aug 2011 No development reported - Phase-I for Psychiatric disorders in USA (unspecified route)